.png){kind=logo}
Clinical research at the OVID Clinic Berlin
We want to continuously improve the care of our patients. This is why we participate in research studies or conduct research ourselves on psychotherapeutic and psychopharmacological topics in the outpatient area of the OVID Clinic Berlin. These studies are intended to contribute to the development and evaluation of innovative approaches.
This includes researching the effectiveness and the process of continuing training in augmented psychotherapy for doctors and psychotherapists and evaluating the treatment concept of the OVID Clinic Berlin itself. We are also a center for studies on the clinical application of psychedelic substances for the treatment of psychological disorders.
Upcoming: Study on the safety and efficacy of an oral LSD formulation in the treatment of generalized anxiety disorder
The OVID Clinic Berlin is participating in a clinical phase III study to investigate an oral LSD formulation (MM-120) for the treatment of generalized anxiety disorder in adults. The study is being conducted on behalf of the sponsor MindMed. Further information on the start of the recruitment phase and the inclusion and exclusion criteria will be found here shortly.
Register for our newsletter to get informed about study initiation.
Recruitment completed: Study on the efficacy of 5-MeO-DMT in the treatment of treatment-resistant depression
Since April 2024, we have been participating as a study center in a clinical trial for the treatment of treatment-resistant depression with the psychedelic compound BPL-003 (5-MeO-DMT).
What is the study about?
The aim of the study is to investigate whether and at what dosage the compound BPL-003 (intranasal 5-MeO-DMT) in combination with psychological support can help patients suffering from treatment-resistant depression who have not yet had a positive course of treatment.
The aim is to investigate the safety and effectiveness of a single administration of the active substance in a placebo-controlled study.
Who is organizing the study?
This is a Phase IIb approval study by Beckley Psytech (UK), in which 40 study centers worldwide are participating.
The study schedule
225 participants from 6 countries will be able to take part in the study at 40 study centers. Study participation lasts up to 16 weeks in total and comprises several phases with a total of 11 appointments, of which at least 9 must take place on site:
-
A screening period of max. six weeks duration
-
Psychological preparation sessions (approx. two weeks)
-
One substance session and integration sessions (approx. two weeks)
-
Follow-up discussions and visits (approx. six weeks)
-
During participation in the study, some of the test subjects receive the active substance, while others receive a placebo. If they have received a placebo, under certain circumstances they can take part in an open extended part of the study (approx. nine weeks), which includes a further session using the active substance.
Further information on the sponsor of the study can be found on the Beckley Psytech website or more generally at ClinicalTrials.gov.
Would you like to take part or do you have any questions?
